Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SGMT with free AI briefings, catalyst countdowns, and dilution alerts.

SGMT · Sagimet Biosciences Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$275.8M Cash on Hand
71.3mo Cash Runway
Follow SGMT by email Get an email when SGMT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SGMT, unsubscribe in one click. Privacy

📣 What SGMT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Denifanstat (TVB-2640) Acne Vulgaris Phase 3 · NCT07863193 Recruiting
3-V Bioscience-2640 Metabolic Syndrome Phase 1/2 · NCT02948569 Completed
[14C]-TVB-2640 Healthy Volunteers Phase 1 · NCT05657834 Completed
TVB-3567 Acne Phase 1 · NCT06989840 Recruiting

Also used in these trials (approved or third-party drugs, not SGMT's own candidates): Enzalutamide, Resmetirom.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SGMT holds $275.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $11.6M/quarter from operations, an estimated runway of 71.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 29 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SGMT files for a raise →

👥 Who Owns SGMT

Insiders 4% Institutions (179 holders) 77.9% Public and other holders 18.1%
HolderTypeShares% of sharesAs of
Commodore Capital LP Institution (13G, 5%+) 5,507,752 17.96% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 4,751,186 15.49% 2026-06-30
SilverArc Capital Management, LLC Institution (13G, 5%+) 3,745,990 12.21% 2026-09-30
BALYASNY ASSET MANAGEMENT L.P. Institution (13G, 5%+) 3,626,113 11.82% 2026-06-30
David Happel
President & CEO, Director · +1.03M options
Insider 741,570 2.42% 2026-07-20
Elizabeth Rozek
Chief Legal & Admin. Officer · +339,367 options
Insider 224,414 0.73% 2026-07-20
Eduardo Bruno Martins
Chief Medical Officer · +226,000 options
Insider 147,296 0.48% 2026-02-19
George Kemble
Director · +119,402 options
Insider 62,161 0.20% 2026-08-14
Thierry Chauche
Chief Financial Officer · +138,000 options
Insider 59,688 0.19% 2026-02-19

Share count 30,674,855 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SGMT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SGMT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.